AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$SIBN

PISETSKY MICHAEL A. sold $899K of SIBN (indirect holdings)

PISETSKY MICHAEL A. (SVP, Ops & Adm/Chief Legal Ofr) sold 36,241 indirectly-held shares of SI-BONE, Inc. (SIBN) at $24.80 ($0.90M total) on 2026-11-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · PISETSKY MICHAEL A.
Published Nov 6, 2026, 10:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SIBN
Neutral
medium confidence
Mentioned
$SIBN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIBNNeutralLow
01

Why it matters

The disclosed sale reduces the insider's holding but does not indicate a strategic shift; investors may view it as neutral to slightly bearish.

02

Market read

Primary insider sale filing with modest monetary size; limited immediate market impact.

03

What to watch

Execution under a 10b5‑1 plan may mask timing motives; the insider retains a sizable position.

Relevance 4/10Novelty 5/10Timing: post‑market today

Background

Form 4 filing discloses insider transactions required by the SEC; such filings are primary sources of corporate insider activity.

Company-level read

Ticker impact

$SIBNNeutralMedium confidence
Context

SVP Michael Pisesky sold 36,241 shares of SI‑BONE for $898,802 via a 10b5‑1 plan, reducing his stake to 40,167 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

The sale is sizable for a mid‑cap but executed under a pre‑arranged plan, limiting immediate informational content.

Market effects

Sector

Minimal impact on orthopedic device sector; typical insider sales are routine.

Regional

US market only.

Global

Low

Counterpoint

What could challenge this read

The sale could be a routine liquidity event rather than a negative signal.

Key entities

  • company
    SI‑BONE, Inc.

    Medical device company listed on NASDAQ under ticker SIBN.

  • person
    Michael A. Pisesky

    Senior Vice President, Operations & Administration / Chief Legal Officer at SI‑BONE.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SIBN insider trading history →

Related articles

$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

rttnews.com
$SIBNMed

SI-BONE (SIBN) Q3 2026 Earnings Call Transcript

SI-BONE (SIBN) reported Q3 2026 earnings, highlighting 27% international revenue growth and 32% adjusted EBITDA increase. The company launched iFuse Granite Onyx, expanding its market to 650,000 procedures and $5B opportunity. Onyx targets spinal fusion failure points, with early demand exceeding expectations. New DRGs and reimbursement enhancements support growth. The company expects 20%+ revenue growth in Q4 2026.

finance.yahoo.com
$SIBNMed

SiBone Q3 Earnings Call Highlights

SiBone (SIBN) reported Q3 earnings, highlighting strong demand for its Onyx platform, which targets a $1.5B market. Gross profit rose 13.7% to $44.2M, with gross margin at 79.3%. Net loss narrowed to $3.6M. The company reaffirmed 2026 revenue guidance of $231M-$233M and expects Q4 momentum from physician growth and new products.

finance.yahoo.com